Targeting RAS driven human cancer cells with antibodies to upregulated and essential cell-surface proteins

  1. Alexander John Martinko
  2. Charles Truillet
  3. Olivier Julien
  4. Juan Diaz
  5. Max A Horlbeck
  6. Gordon Whiteley
  7. Josip Blonder
  8. Jonathan S Weissman
  9. Sourav Bandyopadhyay
  10. Michael Evans
  11. James A Wells  Is a corresponding author
  1. University of California, San Francisco, United States
  2. Frederick National Laboratory for Cancer Research, United States

Abstract

While there have been tremendous efforts to target oncogenic RAS signaling from inside the cell, little effort has focused on the cell-surface. Here, we used quantitative surface proteomics to reveal a signature of proteins that are upregulated on cells transformed with KRASG12V, and driven by MAPK pathway signaling. We next generated a toolkit of recombinant antibodies to seven of these RAS induced proteins. We found that five of these proteins are broadly distributed on cancer cell lines harboring RAS mutations. In parallel, a cell-surface CRISPRi screen identified integrin and Wnt signaling proteins as critical to RAS transformed cells. We show that antibodies targeting CDCP1, a protein common to our proteomics and CRISPRi datasets, can be leveraged to deliver cytotoxic and immunotherapeutic payloads to RAS transformed cancer cells and report for RAS signaling status in vivo. Taken together, this work presents a technological platform for attacking RAS from outside the cell.

Data availability

The following previously published data sets were used

Article and author information

Author details

  1. Alexander John Martinko

    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4025-959X
  2. Charles Truillet

    Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  3. Olivier Julien

    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7068-7299
  4. Juan Diaz

    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  5. Max A Horlbeck

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3875-871X
  6. Gordon Whiteley

    Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, United States
    Competing interests
    No competing interests declared.
  7. Josip Blonder

    Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, United States
    Competing interests
    No competing interests declared.
  8. Jonathan S Weissman

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2445-670X
  9. Sourav Bandyopadhyay

    Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3120-923X
  10. Michael Evans

    Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  11. James A Wells

    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States
    For correspondence
    jim.wells@ucsf.edu
    Competing interests
    James A Wells, Celgene Corp provided some of the funding for this work.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8267-5519

Funding

National Institutes of Health (CA191018)

  • Alexander John Martinko
  • Olivier Julien
  • James A Wells

Celgene (GM097316)

  • Alexander John Martinko
  • James A Wells

National Institutes of Health (GM097316)

  • Alexander John Martinko
  • Olivier Julien
  • James A Wells

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (AN110806-03C) of the University of California San Francisco. Animals that were studied with PET/CT were anesthitized with a mixture of isoflurane/oxygen and humanely euthanized with CO2(g).

Copyright

© 2018, Martinko et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 10,798
    views
  • 1,828
    downloads
  • 74
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Alexander John Martinko
  2. Charles Truillet
  3. Olivier Julien
  4. Juan Diaz
  5. Max A Horlbeck
  6. Gordon Whiteley
  7. Josip Blonder
  8. Jonathan S Weissman
  9. Sourav Bandyopadhyay
  10. Michael Evans
  11. James A Wells
(2018)
Targeting RAS driven human cancer cells with antibodies to upregulated and essential cell-surface proteins
eLife 7:e31098.
https://doi.org/10.7554/eLife.31098

Share this article

https://doi.org/10.7554/eLife.31098

Further reading

    1. Biochemistry and Chemical Biology
    Shu-Ting Zhang, Shi-Kai Deng ... Ning-Yi Zhou
    Research Article

    1-Naphthylamine (1NA), which is harmful to human and aquatic animals, has been used widely in the manufacturing of dyes, pesticides, and rubber antioxidants. Nevertheless, little is known about its environmental behavior and no bacteria have been reported to use it as the growth substrate. Herein, we describe a pathway for 1NA degradation in the isolate Pseudomonas sp. strain JS3066, determine the structure and mechanism of the enzyme NpaA1 that catalyzes the initial reaction, and reveal how the pathway evolved. From genetic and enzymatic analysis, a five gene-cluster encoding a dioxygenase system was determined to be responsible for the initial steps in 1NA degradation through glutamylation of 1NA. The γ-glutamylated 1NA was subsequently oxidized to 1,2-dihydroxynaphthalene which was further degraded by the well-established pathway of naphthalene degradation via catechol. A glutamine synthetase-like (GS-like) enzyme (NpaA1) initiates 1NA glutamylation, and this enzyme exhibits a broad substrate selectivity toward a variety of anilines and naphthylamine derivatives. Structural analysis revealed that the aromatic residues in the 1NA entry tunnel and the V201 site in the large substrate-binding pocket significantly influence NpaA1’s substrate preferences. The findings enhance understanding of degrading polycyclic aromatic amines, and will also enable the application of bioremediation at naphthylamine contaminated sites.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Qiong He, Miao-Miao Zhao ... Jin-Kui Yang
    Research Article

    Diabetes, a prevalent chronic condition, significantly increases the risk of mortality from COVID-19, yet the underlying mechanisms remain elusive. Emerging evidence implicates Cathepsin L (CTSL) in diabetic complications, including nephropathy and retinopathy. Our previous research identified CTSL as a pivotal protease promoting SARS-CoV-2 infection. Here, we demonstrate elevated blood CTSL levels in individuals with diabetes, facilitating SARS-CoV-2 infection. Chronic hyperglycemia correlates positively with CTSL concentration and activity in diabetic patients, while acute hyperglycemia augments CTSL activity in healthy individuals. In vitro studies reveal high glucose, but not insulin, promotes SARS-CoV-2 infection in wild-type cells, with CTSL knockout cells displaying reduced susceptibility. Utilizing lung tissue samples from diabetic and non-diabetic patients, alongside Leprdb/dbmice and Leprdb/+mice, we illustrate increased CTSL activity in both humans and mice under diabetic conditions. Mechanistically, high glucose levels promote CTSL maturation and translocation from the endoplasmic reticulum (ER) to the lysosome via the ER-Golgi-lysosome axis. Our findings underscore the pivotal role of hyperglycemia-induced CTSL maturation in diabetic comorbidities and complications.